The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

• Published in: Cell & bioscience Vol. 13; no. 1; pp. 211 - 20
• Main Authors: Cheng, Bisheng, Li, Lingfeng, Wu, Yongxin, Luo, Tianlong, Tang, Chen, Wang, Qiong, Zhou, Qianghua, Wu, Jilin, Lai, Yiming, Zhu, Dingjun, Du, Tao, Huang, Hai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.11.2023; BioMed Central; BMC
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Analysis; Annexins; Apoptosis; Cancer; Cancer therapies; Castration; Cell culture; Cell growth; Chemotherapy; Development and progression; Docetaxel; Drug resistance; Gene expression; Genetic aspects; Health aspects; Medical prognosis; Oncology; Overexpression; Plasmids; Prostate cancer; Ribonucleotide reductase; RRM2; Senescence; Survival analysis; Tumor cell lines; Tumors; Xenografts; United States > US; California; Oncology; Chemotherapy; RRM2; Prostate cancer; Docetaxel

Prostate cancer is a leading cause of cancer-related deaths among men worldwide. Docetaxel chemotherapy has proven effective in improving overall survival in patients with castration-resistant prostate cancer (CRPC), but drug resistance remains a considerable clinical challenge. We explored the role...